Medtronic plc stock dips after strong Q1 FY2027 figures and steady analyst support

Published on 09/10/2026 at 22:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medtronic plc stock trades near USD 92 on the NYSE as of September 10, 2026, after reporting Q1 FY2027 revenue of USD 9.76 billion, up 13.7 percent year over year. Analysts keep a Moderate Buy stance with an average price target around USD 103.92 and a quarterly dividend of USD 0.72 declared.

Reinraumfertigung mit Technikern bei Montage medizintechnischer Präzisionsinstrumente — Medtronic plc (ISIN IE00BTN1Y115) Reinraum-Fertigung zeigt Techniker bei der Montage medizinischer Präzisionsinstrumente sorgfältig, Illustration mit AI erstellt.

Medtronic plc stock (ISIN IE00BTN1Y115) is trading around USD 92 on the New York Stock Exchange as of September 10, 2026, after the medical technology group reported strong fiscal first-quarter 2027 results with revenue of USD 9.76 billion and non-GAAP EPS of USD 1.45, both above market expectations.

Q1 FY2027 earnings show double-digit growth

Medtronic plc, one of the largest global medical device makers, delivered fiscal first-quarter 2027 revenue of about USD 9.8 billion, which represents 13.7 percent organic growth compared with the prior-year quarter, while non-GAAP diluted EPS increased 15.1 percent to USD 1.45 per share, according to Yahoo Finance on September 10, 2026.

The quarterly EPS of USD 1.45 also beat analyst consensus estimates of USD 1.39 by USD 0.06, while revenue growth of 13.7 percent year over year underlined the recovery in core businesses, as reported by MarketBeat in its latest Medtronic overview.

For investors, this combination of double-digit revenue growth and mid-teens EPS expansion in Q1 FY2027 sets a higher bar for the rest of the fiscal year, particularly as the company has raised its outlook following stronger demand for heart devices, as highlighted by MarketBeat.

Dividend and institutional interest support the shares

Alongside the earnings strength, Medtronic plc has confirmed its shareholder-return profile with a quarterly cash dividend of USD 0.72 per share, corresponding to an annualized payout of USD 2.88 and a dividend yield of roughly 3.1 percent based on recent prices, as detailed by MarketBeat on September 10, 2026.

That dividend of USD 0.72 per quarter comes on top of Medtronic's status as a long-established dividend payer, with forward dividend yield cited around 3.06 percent and the shares trading about 16 percent below a fair value estimate of USD 112, according to Morningstar data as of September 7, 2026.

Institutional investors continue to play a major role in the shareholder base, with roughly 82 percent of the stock held by institutions and hedge funds, as noted by MarketBeat in its September 10, 2026 coverage.

Analysts keep a Moderate Buy stance and set upside targets

Analyst sentiment on Medtronic plc stock remains constructive, with a consensus rating of Moderate Buy and an average price target of USD 103.92, implying upside potential from the current price zone, according to MarketBeat on September 10, 2026.

Within that broader view, Wells Fargo analyst Larry Biegelsen maintains Medtronic with a Buy rating and a target price of USD 104, signaling confidence that earnings momentum and device demand can drive a modest re-rating, as reported by Futunn on September 10, 2026.

Similarly, Citi analyst Joanne Wuensch maintains a Buy rating on Medtronic plc stock with a target price of USD 110, emphasizing long-term growth opportunities in core franchises and pipeline assets, according to Futunn on September 10, 2026.

The spread between the current trading level near USD 92 and analyst targets around USD 104 to USD 110 illustrates that the market has not fully priced in the recent double-digit revenue and EPS growth, but also that investors are weighing risks such as execution on portfolio changes and regulatory scrutiny in key markets.

Upcoming earnings expectations add another checkpoint

Looking ahead, Medtronic plc's next quarterly checkpoint will be the results for the quarter ending in October 2026, for which the Zacks Consensus Estimate currently stands at EPS of USD 1.34 per share, slightly below the most recent quarterly figure of USD 1.45, according to Zacks on September 9, 2026.

Zacks notes that Medtronic delivered a positive earnings surprise of 4.32 percent in its last reported quarter by beating the USD 1.39 per share consensus, but currently expects the company to miss the upcoming estimate by 0.62 percent, underlining that the earnings trajectory is watched closely by the market and may act as a catalyst for the stock around the next reporting date, as summarized by Zacks.

The precise date for the next earnings release has not been formally set in the sources reviewed, but the October 2026 period ending implies that investors are likely to see the next numbers in late calendar 2026, adding to the list of upcoming events that may influence Medtronic plc stock performance.

Stock trades below early-2026 level and near recent closes

From a chart perspective, Medtronic plc stock has eased somewhat compared with the start of the year: the shares were trading at USD 96.13 on January 1, 2026 and are now around USD 92, corresponding to a decline of roughly 4 percent year to date, as highlighted by MarketBeat.

Recent closing data show Medtronic plc stock at USD 91.89 at the NYSE close on September 9, 2026, only slightly below the prior close of USD 92.32 on September 10, 2025, which means a hypothetical USD 100 investment one year earlier would now be worth USD 99.53, a decline of 0.47 percent excluding dividends, according to finanzen.ch on September 10, 2026.

Intraday price snapshots show Medtronic plc stock quoted at about USD 91.46 on the NYSE with a small negative move of 0.46 percent as of September 10, 2026, 3:03 p.m. Eastern Time, according to BusinessQuant, which places the share price close to the recent closing levels cited by other data providers.